La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Ocugen Gestion

Gestion contrôle des critères 2/4

Le PDG Ocugen's est Shankar Musunuri, nommé en Sep2013, a un mandat de 10.92 ans. La rémunération annuelle totale est $ 4.54M, composée du salaire de 16.7% et des bonus 83.3%, y compris les actions et options de la société. détient directement 0.65% des actions de la société, d'une valeur de $ 2.42M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.5 ans et 4.5 ans.

Informations clés

Shankar Musunuri

Directeur général

US$4.5m

Rémunération totale

Pourcentage du salaire du PDG	16.7%
Durée du mandat du directeur général	10.9yrs
Propriété du PDG	0.7%
Durée moyenne d'occupation des postes de direction	1.5yrs
Durée moyenne du mandat des membres du conseil d'administration	4.5yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Shankar Musunuri a-t-elle évolué par rapport aux bénéfices de Ocugen?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$45m
Mar 31 2024	n/a	n/a	-US$58m
Dec 31 2023	US$5m	US$758k	-US$63m
Sep 30 2023	n/a	n/a	-US$82m
Jun 30 2023	n/a	n/a	-US$90m
Mar 31 2023	n/a	n/a	-US$86m
Dec 31 2022	US$8m	US$715k	-US$87m
Sep 30 2022	n/a	n/a	-US$74m
Jun 30 2022	n/a	n/a	-US$63m
Mar 31 2022	n/a	n/a	-US$69m
Dec 31 2021	US$8m	US$541k	-US$58m
Sep 30 2021	n/a	n/a	-US$48m
Jun 30 2021	n/a	n/a	-US$47m
Mar 31 2021	n/a	n/a	-US$38m
Dec 31 2020	US$2m	US$500k	-US$34m
Jun 30 2020	n/a	n/a	-US$30m
Mar 31 2020	n/a	n/a	-US$18m
Dec 31 2019	US$572k	US$420k	-US$20m
Sep 30 2019	n/a	n/a	-US$39m
Jun 30 2019	n/a	n/a	-US$18m
Mar 31 2019	n/a	n/a	-US$19m
Dec 31 2018	US$431k	US$420k	-US$18m

Rémunération vs marché: La rémunération totale de Shankar ($USD 4.54M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 2.44M ).

Rémunération et revenus: La rémunération de Shankar a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Shankar Musunuri (60 yo)

10.9yrs

Titularisation

US$4,535,231

Compensation

Dr. Shankar Musunuri, Ph D., MBA, is the Co-Founder of Ocugen, Inc. since September 2013 and has been its Chairman and Chief Executive Officer and Director since September 27, 2019. He served as Interim Pr...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Shankar Musunuri	Co-Founder	10.9yrs	US$4.54m	0.65% $ 2.4m
Uday Kompella	Co-founder & Independent Director	10.9yrs	US$102.13k	0.24% $ 909.6k
Michael Breininger	Chief Accounting Officer & Corporate Controller	less than a year	US$226.94k	pas de données
Arun Upadhyay	Chief Scientific Officer and Head of Research & Development	1.9yrs	US$1.38m	0.037% $ 138.0k
John Kouch	General Counsel	no data	pas de données	pas de données
Tiffany Hamilton	AVP & Head of Corporate Communications	no data	pas de données	pas de données
Kristen Craft	Head of People & Culture	less than a year	pas de données	pas de données
Michael Shine	Senior Vice President of Commercial	3.2yrs	pas de données	pas de données
Jyothy Pillai	VP & Head of Regulatory & Quality	1.5yrs	pas de données	pas de données
Huma Qamar	Chief Medical Officer	less than a year	pas de données	0.00057% $ 2.1k
Durgaprasad Annavajjula	VP, Head of Program Management & Chief of Staff	less than a year	pas de données	pas de données

1.5yrs

Durée moyenne de l'emploi

41yo

Âge moyen

Gestion expérimentée: L'équipe de direction de OCGN n'est pas considérée comme expérimentée (ancienneté moyenne 1.5 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Shankar Musunuri	Co-Founder	4.9yrs	US$4.54m	0.65% $ 2.4m
Uday Kompella	Co-founder & Independent Director	4.9yrs	US$102.13k	0.24% $ 909.6k
Prabhavathi Fernandes	Lead Independent Director	4.3yrs	US$124.63k	0% $ 0
Marna Whittington	Independent Director	2.4yrs	US$103.32k	0.00035% $ 1.3k
Carl Regillo	Member of Retina Scientific Advisory Board	4.8yrs	pas de données	pas de données
David Boyer	Member of Retina Scientific Advisory Board	no data	pas de données	pas de données
Bruce Forrest	Vaccine Scientific Advisory Board Member	3.7yrs	pas de données	pas de données
Junge Zhang	Independent Director	4.9yrs	US$87.13k	0.40% $ 1.5m
Geeta Lalwani	Member of Retina Scientific Advisory Board	no data	pas de données	pas de données
Kirsten Castillo	Independent Director	4.3yrs	US$110.82k	0.017% $ 64.5k
Satishchandran Chandrasekhar	Vaccine Scientific Advisory Board Member	3.7yrs	pas de données	pas de données
Mark Pennesi	Member of Retina Scientific Advisory Board	4.8yrs	pas de données	pas de données

4.5yrs

Durée moyenne de l'emploi

60yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de OCGN sont considérés comme expérimentés (ancienneté moyenne 4.5 ans).

Ocugen Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Ocugen, Inc., Annual General Meeting, Jun 28, 2024

Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

Insufficient new directors

Ocugen, Inc. Appoints Connie Collingsworth to the Business Advisory Board

Ocugen, Inc. Announces Executive Changes

Recent updates

Consensus revenue estimates increase by 340%

Price target increased by 11% to US$7.00

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

New minor risk - Shareholder dilution

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Ocugen, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 Armada Clinical Trial of OCU410 —A Novel Modifier Gene Therapy

Ocugen, Inc. Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

Ocugen, Inc. Announces First Patient Dosed in Phase 3 Limelight Clinical Trial for Ocu400—First Gene Therapy in Phase 3 with A Broad Retinitis Pigmentosa Indication

Law Offices of Howard G. Smith Alleges Lawsuit Against Ocugen, Inc

Ocugen, Inc. Announces Positive Outcome of the Data and Safety Monitoring Board Review for its Phase 1/2 ArMaDa Clinical Trial for OCU410

Ocugen, Inc., Annual General Meeting, Jun 28, 2024

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Ocugen, Inc. Announces Ocu400 Modifier Gene Therapy Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial

Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy

Ocugen Provides Business Update

Ocugen, Inc. to Report Q4, 2023 Results on Apr 02, 2024

Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

New major risk - Share price stability

Price target increased by 19% to US$6.33

Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

New minor risk - Share price stability

Price target increased by 13% to US$4.50

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

Insufficient new directors

Forecast to breakeven in 2026

Ocugen, Inc. Gains FDA Alignment on Key Aspects of OCU400 —Modifier Gene Therapy—Pivotal Phase 3 Study Design

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—For Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Price target decreased by 17% to US$4.00

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST --Modifier Gene Therapy-- for Stargardt Disease

Ocugen, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Ocugen, Inc. Announces Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH NIAID Project NextGen for Inclusion in Clinical Trials

Ocugen, Inc. Appoints Connie Collingsworth to the Business Advisory Board

Ocugen, Inc. Announces Executive Changes

Ocugen, Inc. Announces Positive Clinical Study Update from the Phase 1/2 Trial of Ocu400, A Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

Ocugen, Inc. to Report Q2, 2023 Results on Aug 21, 2023

Ocugen, Inc. announced delayed 10-Q filing

Price target decreased by 19% to US$3.90

Independent Director recently bought US$100k worth of stock

Ocugen, Inc. Announces Business Advisory Board

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Ocugen, Inc. has completed a Follow-on Equity Offering.

Consensus revenue estimates fall by 58%

No longer forecast to breakeven

Co-Founder exercised options and sold US$75k worth of stock

Ocugen, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Ocugen, Inc. Appoints Quan A. Vu as Chief Business Officer

Co-Founder notifies of intention to sell stock

Ocugen, Inc. Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-Bridging and Broadening Study: Both Co-Primary Endpoints Met

Forecast to breakeven in 2025

Co-Founder notifies of intention to sell stock

Ocugen, Inc Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

High number of new directors

Ocugen, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Co-Founder exercised options and sold US$115k worth of stock

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

Ocugen, Inc. Announces Publication of Comprehensive Review of BBV152 in Frontiers in Immunology

Ocugen announces peer-reviewed publication on COVID-19 vaccine

Ocugen, Inc. Announces Board Changes

Price target decreased to US$7.00

Ocugen initiated with Buy at Mizuho citing favorable setup ahead of key readout

Consensus forecasts updated

No longer forecast to breakeven

Consensus forecasts updated